Business context and reporting period
The supplied filing is GlycoMimetics, Inc.’s Form 10-K for the fiscal year ended December 31, 2019; this does not match the request metadata naming Crescent Biopharma, Inc. It reports an annual period, not a standalone fourth quarter. GlycoMimetics is a clinical-stage biotechnology company with no approved products or product-sales revenue. Its lead candidate, uproleselan, is being developed for acute myeloid leukemia (AML).
Financial performance and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $47.0 million | $40.1 million |
| General and administrative expense | $14.4 million | $11.4 million |
| Total operating expenses | $61.4 million | $51.5 million |
| Operating loss | $61.4 million | $51.5 million |
| Interest income | $3.5 million | $3.2 million |
| Net loss | $57.9 million | $48.3 million |
| Basic and diluted loss per share | $1.34 | $1.18 |
| Cash and cash equivalents at year-end | $158.2 million | $209.9 million |
| Net cash used in operating activities | $52.0 million | $43.3 million |
| Total liabilities at year-end | $13.8 million | $9.4 million |
Operating expenses rose 19% year over year, principally from increased clinical development activity and personnel costs; lower manufacturing and formulation costs partly offset the increase. Net loss widened by $9.6 million. No gross or operating margin is meaningful because the company reported no revenue. The filing reports no borrowings; liabilities primarily include accrued expenses and operating lease obligations. Year-end current assets were $162.5 million and current liabilities $11.0 million. Management estimated existing cash would fund operating and capital requirements into 2022, subject to assumptions and development spending.
Programs, changes and notable events
- Uproleselan: A global Phase 3 trial in relapsed/refractory AML was underway, targeting about 380 patients; enrollment began in late 2018 and management expected completion in the second half of 2021. An NCI-sponsored trial in older, previously untreated AML patients began enrolling in 2019 and is expected to enroll about 670 patients.
- Prior Phase 1/2 uproleselan results included a 41% CR/CRi rate and median overall survival of 8.8 months in the relapsed/refractory cohort at the recommended dose. These results were compared with historical controls and are not confirmatory Phase 3 evidence.
- GMI-1359 entered a Phase 1b trial in hormone-receptor-positive breast cancer with bone metastases in late 2019; the first patient was dosed in January 2020. FDA orphan-drug and rare-pediatric-disease designations for osteosarcoma were also granted in January 2020.
- Rivipansel’s pivotal Phase 3 trial failed to meet its primary and key secondary efficacy endpoints. Pfizer gave notice in February 2020 that it would terminate the license effective April 5, 2020; development and commercialization rights are expected to revert to GlycoMimetics.
- In January 2020, Apollomics licensed uproleselan and GMI-1687 in Greater China. GlycoMimetics received $9.0 million upfront and may earn approximately $180 million in development, regulatory and sales milestones, plus tiered royalties from high single digits to 15%. These potential payments are contingent and not assured.
Outlook, risks and contingencies
- The company expects continued losses and rising development costs; it has an accumulated deficit of $258.4 million and says additional funding will be needed. Its cash-runway estimate into 2022 is forward-looking and may prove inaccurate.
- Key uncertainties include Phase 3 efficacy and safety, trial enrollment and timing, regulatory approval, manufacturing scale-up, competition, reimbursement and the need for future financing, which could dilute shareholders or require licensing rights.
- GlycoMimetics relies on third parties for clinical-trial and drug manufacturing services and has no commercial sales or distribution infrastructure.
- The filing cites the coronavirus outbreak as a possible source of disruption to Apollomics’ Greater China development activities and potential milestone timing.
- Management reported effective disclosure controls and internal control over financial reporting; the auditor gave unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for GlycoMimetics, Inc., not Crescent Biopharma, Inc.
- Track uproleselan Phase 3 enrollment, completion timing, clinical results and any regulatory developments.
- Review the complete rivipansel Phase 3 data and the transition of rights and responsibilities from Pfizer.
- Monitor Apollomics’ development progress, the terms and receipt of any milestones or royalties, and whether the $9.0 million upfront payment is reflected in post-year-end reporting.
- Assess cash consumption, financing needs and whether the projected runway into 2022 remains supportable.